Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer

NCT07506876 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer - Infiltrating Ductal Carcinoma
HER-2 Positive Breast Cancer

Interventions

DRUG: Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy

Sponsor

Legacy Health System